相关实验视频
Updated: Jun 26, 2025

10:28
Body Composition and Metabolic Caging Analysis in High Fat Fed Mice
Published on: May 24, 2018
15.5K
用于治疗肥胖症的GLP-1导向NMDA受体对抗作用
Jonas Petersen1,2, Mette Q Ludwig1, Vaida Juozaityte1
1Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Nature
|May 15, 2024
概括
一种新型双模分子结合了N-甲基-D-阿斯巴达酸 (NMDA) 受体对抗性和葡萄糖类-1 (GLP-1) 受体对抗性. 这种方法有效地扭转了动物模型中的肥胖和代谢疾病症状.
科学领域:
- 神经科学
- 代谢疾病研究
- 药理学
背景情况:
- N-甲基-D-酸盐 (NMDA) 受体对大脑功能至关重要,它们的调节与体重平衡有关.
- 葡萄糖类-1 (GLP-1) 受体信号在代谢调节中起作用.
- 肥胖和新陈代谢疾病的现有治疗方法往往有局限性.
研究的目的:
- 设计和开发一种融合NMDA受体对抗性和GLP-1受体对抗性的双模分子.
- 研究这种单分子方法对肥胖,高血糖和脂质失调的治疗潜力.
- 通过GLP-1受体输送评估向性NMDA受体对抗的安全性和有效性.
主要方法:
- 开发一种双模分子,结合NMDA受体抗剂 (MK-801) 和GLP-1受体激动剂.
- 使用GLP-1受体介导的输送以向MK-801分发到特定的大脑区域.
- 在动物模型中对饮食诱导的肥胖和代谢疾病的临床前评估.
主要成果:
- 在动物模型中,双模分子有效逆转肥胖,高血糖和脂质失调.
- 将NMDA受体抗剂向GLP-1受体表达脑部区域,可以减轻单独治疗的不良影响.
- 由于GLP- 1导向的NMDA受体对抗作用,在下丘脑和脑干中表现出神经可塑性变化.
结论:
- 介导向使细胞特异性调节离子受体成为可能.
- 单分子组合的GLP-1受体激动性和NMDA受体对抗性为肥胖提供了一个有前途的治疗策略.
- 这种方法有可能对代谢疾病进行安全有效的治疗.
相关概念视频
Glucagon-like Receptor Agonists
318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Regulation of Food Intake
224
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
224
Oral Hypoglycemic Agents: Glinides
153
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Antiepileptic Drugs: Glutamate Antagonists
321
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
321
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192

